




Mark Berlin (Autor)

# Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs

Mark Berlin

## Predicting Oral Absorption of Poorly Soluble Weakly Basic Drugs



Cuvillier Verlag Göttingen  
Internationaler wissenschaftlicher Fachverlag

<https://cuvillier.de/de/shop/publications/7128>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



# Index

<b>1</b>	<b>Introduction .....</b>	<b>1</b>
1.1	Drug transit through the upper GI tract.....	2
1.2	Determinants of drug absorption .....	4
1.2.1	The biopharmaceutics classification system .....	4
1.2.2	The biopharmaceutics drug disposition classification system.....	5
1.2.3	The developability classification system .....	6
1.3	Weak bases and the GI tract.....	7
1.3.1	pH in the GI tract .....	7
1.3.2	Bile salts and food in the GI tract .....	9
1.3.3	Gastric emptying .....	10
1.4	Simulation of <i>in vivo</i> drug dissolution .....	10
1.4.1	Dissolution media simulating GI fluids .....	10
1.4.2	Simulation of GI dissolution conditions .....	11
1.5	Drug permeability assessment .....	14
1.6	Physiologically based pharmacokinetic modeling .....	16
1.6.1	PBPK modeling approaches .....	16
1.6.2	Software for PBPK modeling.....	17
1.6.2.1	<i>MATLAB<sup>®</sup> and STELLA<sup>®</sup></i> .....	17
1.6.2.2	<i>Commercial software (Simcyp<sup>®</sup>, GastroPlus<sup>®</sup>, PK-Sim<sup>®</sup>) and GI-Sim<sup>®</sup></i> .....	18
1.7	Aims of this work .....	20
<b>2</b>	<b>Materials and Methods.....</b>	<b>21</b>
2.1	Materials.....	21
2.1.1	Chemicals .....	21
2.1.2	Model substance cinnarizine.....	22
2.1.3	Model substance atazanavir .....	24
2.2	Methods.....	28
2.2.1	HPLC-UV setup.....	28
2.2.2	Biorelevant media .....	29
2.2.3	Solubility assessment.....	31
2.2.4	Dissolution experiments .....	33
2.2.5	“Dumping” experiments.....	33
2.2.6	Transfer experiments .....	33
2.2.7	WinNonLin <sup>®</sup> - assessment of pharmacokinetics of API formulations .....	38
2.2.8	STELLA <sup>®</sup> .....	39
2.2.9	Simcyp <sup>®</sup> .....	47
2.2.10	Statistical comparison of predicted plasma profiles using different transfer experiment approaches .....	51



<b>3</b>	<b>Results</b>	<b>52</b>
3.1	Cinnarizine – investigation of <i>in vitro</i> behavior	52
3.1.1	Solubility results	52
3.1.2	Dissolution of cinnarizine tablets in biorelevant media	53
3.1.3	Dumping of pure cinnarizine	57
3.1.4	Investigation of supersaturation and precipitation of cinnarizine during transfer experiments	58
3.2	Cinnarizine - <i>in silico</i> plasma profile simulation	66
3.2.1	Evaluation of distribution and elimination kinetics of various cinnarizine tablets using WinNonLin®	66
3.2.2	STELLA® model - investigation of permeability restrictions of cinnarizine using fed state simulations	67
3.2.3	STELLA® “dissolution-only” vs. “supersaturation and precipitation” PBPK model in cinnarizine fasted state simulations	69
3.2.4	STELLA® statistical comparison analysis of different transfer rates	73
3.2.5	STELLA® sensitivity analysis of cinnarizine plasma profile predictions	74
3.2.6	Summary of cinnarizine plasma profile simulations using Simcyp®	77
3.3	Summary of the cinnarizine investigation and formulation suggestions	78
3.4	Atazanavir sulfate – investigation of <i>in vitro</i> behavior	80
3.4.1	Solubility results	80
3.4.1.1	<i>Equilibrium solubility</i>	80
3.4.1.2	<i>Kinetic solubility</i>	82
3.4.2	Dissolution results of atazanavir sulfate capsules in biorelevant media	83
3.4.3	Dumping results of atazanavir sulfate	87
3.4.4	Investigation of the atazanavir sulfate concentration profile during simulated transfer from the stomach to the intestine	88
3.5	Atazanavir sulfate - <i>in silico</i> plasma profile simulation	95
3.5.1	Evaluation of distribution and elimination kinetics of atazanavir using WinNonLin® analysis of literature PK data	95
3.5.2	Permeability evaluation of atazanavir	96
3.5.3	STELLA® plasma profile predictions of atazanavir capsules in the fasted state	97
3.5.4	STELLA® sensitivity analysis on atazanavir plasma profile predictions	104
3.6	Summary of atazanavir plasma profile simulations using Simcyp®	109
3.7	Summary of the atazanavir investigation and formulation suggestions	110
<b>4</b>	<b>General discussion and conclusions</b>	<b>113</b>
4.1	Choosing the right <i>in vitro</i> investigation approach	113
4.2	Formulation enhancement approaches for weakly basic drugs	120
4.3	Choosing the right PBPK modeling approach	122
4.3.1	Development and evolution of the STELLA® model	122



4.3.2	Self-built versus commercial PBPK models (STELLA <sup>®</sup> versus Simcyp <sup>®</sup> ) .....	123
4.3.2.1	<i>Input of release and dissolution profiles</i> .....	124
4.3.2.2	<i>Opportunities for simulating pharmacokinetics of modified release formulations</i> .....	125
4.3.2.3	<i>Input of permeability</i> .....	125
4.3.2.4	<i>Middle-out and Bottom-up modeling approaches</i> .....	126
4.3.2.5	<i>Virtual populations</i> .....	127
4.3.2.6	<i>Summary</i> .....	127
4.4	Outlook .....	128
<b>5</b>	<b>Summary</b> .....	<b>131</b>
<b>6</b>	<b>German Summary (Deutsche Zusammenfassung)</b> .....	<b>137</b>
<b>7</b>	<b>Appendix</b> .....	<b>143</b>
7.1	STELLA <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions.....	143
7.2	STELLA <sup>®</sup> sensitivity analysis of atazanavir sulfate plasma profile predictions.....	145
7.3	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine .....	148
7.3.1	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fasted state .....	148
7.3.2	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine in the fed state .....	155
7.3.3	Simcyp <sup>®</sup> sensitivity analysis of cinnarizine plasma profile predictions .....	161
7.3.4	Simcyp <sup>®</sup> plasma profile predictions of cinnarizine using fitted Vd.....	172
7.4	Simcyp <sup>®</sup> plasma profile predictions of atazanavir .....	176
7.4.1	Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fasted state.....	176
7.4.2	Simcyp <sup>®</sup> plasma profile predictions of atazanavir in the fed state.....	184
7.4.3	Simcyp <sup>®</sup> sensitivity analysis of atazanavir plasma profile predictions.....	188
<b>8</b>	<b>References</b> .....	<b>203</b>
<b>9</b>	<b>Curriculum Vitae</b> .....	<b>216</b>
9.1	Personal Information .....	216
9.2	Professional experience .....	216
9.3	Education .....	217
<b>10</b>	<b>Scientific Publications</b> .....	<b>218</b>
10.1	Papers .....	218
10.2	Posters .....	218
<b>11</b>	<b>Academic Teachers</b> .....	<b>218</b>